Interactions of human tenascin-X domains with dermal extracellular matrix molecules. by Egging, D.F. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/51632
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Arch Dermatol Res (2007) 298:389–396 
DOI 10.1007/s00403-006-0706-9
123
ORIGINAL PAPER
Interactions of human tenascin-X domains with dermal 
extracellular matrix molecules
David Egging · Franka van den Berkmortel · 
Glen Taylor · Jim Bristow · Joost Schalkwijk 
Received: 5 July 2006 / Revised: 28 August 2006 / Accepted: 2 September 2006 / Published online: 11 October 2006
©  Springer-Verlag 2006
Abstract Tenascin-X (TNX) is a large 450 kDa extra-
cellular matrix protein expressed in a variety of tissues
including skin, joints and blood vessels. DeWciency of
TNX causes a recessive form of Ehlers–Danlos syn-
drome characterized by joint hypermobility, skin fra-
gility and hyperextensible skin. Skin of TNX deWcient
patients shows abnormal elastic Wbers and reduced col-
lagen deposition. The mechanism by which TNX deW-
ciency leads to connective tissue alterations is unknown.
Here we report that C-terminal domains of human
TNX bind to major dermal Wbrillar collagens and trop-
oelastin. We have mapped these interactions to the
Wbronectin type III repeat 29 (FNIII29) and the C-ter-
minal Wbrinogen domain (FbgX) of TNX. In addition
we found that FNIII29 of TNX accelerates collagen
Wbrillogenesis in vitro. We hypothesize that TNX con-
tributes to matrix stability and is possibly involved in
collagen Wbril formation.
Keywords Tenascin-X · Collagen · Elastin · 
Fibrillogenesis · Ehlers–Danlos syndrome
Introduction
Tenascin-X is a large extracellular matrix glycoprotein
composed of EGF like-repeats, Wbronectin type III
(FNIII) repeats and a C-terminal Wbrinogen domain
(FbgX) [1, 5, 6, 12]. TNX abnormalities are associated
with several pathological conditions [2, 22, 27]. Com-
plete deWciency of TNX in humans leads to a recessive
form of Ehlers Danlos syndrome (EDS) and TNX hap-
loinsuYciency is a cause of hypermobility type EDS.
The skin of TNX deWcient patients is markedly lax with
poor recoil properties and shows easy bruising [2, 14,
20, 22, 27]. We have previously shown TNX to be pres-
ent in the entire dermis of healthy individuals. During
development in mice TNX colocalises with the major
Wbrillar collagens and elastic Wbers in the dermis [3, 22].
Adult TNX deWcient patients show abnormal elastic
Wbers and reduced collagen deposition in skin [28]. The
mechanism by which TNX deWciency leads to altera-
tions in the extracellular matrix (ECM) is unknown.
Mapping of TNX domains that interact with compo-
nents of the elastic Wbers or collagen is therefore an
important step to deWne the role of TNX in connective
tissue biology of human skin.
It has previously been shown that bovine and
murine TNX bind to heparin [13, 16]. In bovine TNX a
conformational heparin-binding site has been identi-
Wed involving FNIII repeats 10 and 11 in the N-terminal
half of the molecule. This heparin-binding site is also
involved in the binding of TNX to decorin, and it was
proposed that TNX interacts with collagen through
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decorin [4]. Minamitani et al. showed that the short
isoform of murine TNX binds directly to collagen type
I, probably through interaction with one of the Wbro-
nectin type III repeats. This short isoform was found to
promote collagen Wbrillogenesis in vitro [18].
The aim of our study was to investigate the molecular
mechanisms of the observed phenotype in TNX-deW-
cient EDS patients. We therefore analyzed interactions
of human TNX with elastic Wber components and with
the major Wbrillar collagens in the dermis (collagen
type I, III and V). We found that the C-terminus of
TNX harbors potential interaction sites with collagens
type I, III and V and tropoelastin (TE), which are con-
stituents of the anatomical structures that are abnor-
mal in the dermis of these patients.
Materials and methods
Expression and puriWcation of recombinant 
TNX fragments
The TNX fragments were ampliWed by PCR with the
primers listed in Table 1 using a previously described
2.7 kb human TNX cDNA [19] as a template. PCR
products were ligated into the pCR2.1TOPO vector
(Invitrogen, Breda, NL) according to the manufac-
turer’s instructions for easy digestion with restriction
enzymes. The pCR2.1 TOPO vectors with inserts were
digested with EcoRI and SalI and cloned into the
EcoRI/SalI site of the pMal-c2X plasmid (Westburg
B.V., Leusden, NL). Subsequently the DNA sequences
coding for FNIII29 and FNIII29–30 of TNX were
cloned into the EcoRI/SalI site of the pGex-4T1 plas-
mid (GE Healthcare Life Sciences, Diegem, BE). The
sequence of the TNX domains was veriWed by dideoxy
sequencing with a 3730 DNA analyzer (Applied Bio-
systems, Nieuwekerk a/d IJssel, NL). TNX fragments
were obtained as maltose binding protein (MBP)
fusion proteins using E.coli TOP10F’ cells (Invitrogen)
according to the manufacturer’s instructions. MBP
fusion proteins were isolated on amylose resin columns
and analyzed for purity with SDS-PAGE. MBP fusion
proteins were incubated with factor Xa (Westburg
B.V.) in an attempt to remove the MBP tag from the
fusion protein according to the manufacturer’s instruc-
tions. FNIII29–30 without tag was obtained by proteolytic
cleavage of FNIII29–30 from a glutathione-S-transfer-
ase (GST) fusion protein bound to a glutathione-
sepharose4B column (GE Healthcare Life Sciences)
according to the manufacturer’s instructions.
Proteins and antibodies
A 100 kDa C-terminal recombinant TNX protein, con-
taining six FNIII repeats and a Wbrinogen domain,
encoded by a 2.7 kb TNX sequence has previously
been described by Tee et al. [19, 23]. MBP–FNIII27–
28, MBP–FNIII28–29, MBP–FNIII29, MBP–FNIII29–
30, MBP–FNIII30–31, MBP–FbgX and FNIII29–30
were obtained as described in the previous section.
Human Collagen type I from Chemicon Interna-
tional (Chemicon International, Temecula, CA, USA),
human collagen type III and V from Rockland Inc
(Tebu-bio, Heerhugowaard, NL). Bovine collagen type
I (acid soluble) was obtained from BD biosciences (BD
Biosciences, Alphen aan den Rijn, NL). Recombinant
bovine tropoelastin (bTE) was a generous gift from Dr.
R. Mecham (Washington University, St. Louis, MO,
USA) [10]. Human recombinant Wbrillin domains, Tb2-
cbEGF11, Tb3-cbFGF11, cbEGF11–14, cbEGF22–23,
cbEGF28–30, tb6-cbEGF32, cbEGF32–36, tb7-cbEGF37,
were generously donated by Dr. P.A. Handford
(Oxford University, Oxford, UK) [7, 9, 11, 17, 24, 25].
BSA and gelatin were obtained from Sigma–Aldrich
(Sigma–Aldrich Chemie B.V., Zwijndrecht, NL). BSA
was used as a negative control. MBP was obtained
from New England Biolabs (Westburg B.V.) and used
as a negative control.
We used monoclonal antibodies speciWc for MBP
(Westburg B.V) and a previously described guinea pig-
anti-TNX serum [22] for detection of untagged
100 kDa TNX and MBP-TNX-domains in our solid-
phase assays. Pre-immunization serum was used as a
Table 1 TNX domains and primers
The EcoRI and SalI restriction sites are underlined in the primer sequences. Each SalI site is preceded by a stop codon (TCA), except
for the Wbrinogen domain, which already contains a stop codon at the 3 end of the sequence
TNX domains Forward primer Reverse primer
FNIII27–28 5-GGAATTCGAGCTACCTCCCCAC-3 5-CTCGTCGACTCACTGACCAGCAGGAGC-3
FNIII28–29 5-CTGAATTCCCTGAAGAGCCCCGC-3 5-TGGGTCGACTCAGCGGGCGGTTCCCTG-3
FNIII29 5-TCAGAATTCTCAAGGCCCCGCCTG-3 5-TGGGTCGACTCAGCGGGCGGTTCCCTG-3
FNIII29–30 5-TCAGAATTCTCAAGGCCCCGCCTG-3 5-GAAGTCGACTCAAGGCTCACTCTCCTC-3
FNIII30–31 5-ACCGAATTCACCCTCAGCCCAGTT-3 5-GTGTCGACTCAGATGCTGGCTGGGG-3
FbgX 5-TCTGAATTCACGGGTGGGCTGCGG-3 5-GGGTCGACAGAGAGGTGGGCAGCA-3
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negative control [22] FNIII29–30 of TNX was detected
with a new aYnity puriWed polyclonal rabbit antiserum,
raised against a MBP–FNIII29–30 antigen.
Collagen Wbrillogenesis assays
Native bovine type I collagen (BD Biosciences,
Alphen aan den Rijn, NL) 2.9 mg/ml in 0.012 N HCl, as
provided by the manufacturer, was dissolved in PBS.
MBP, BSA, MBP–FNIII29, FNIII29–30 and 100 kDa
TNX were added to samples in cuvettes after which the
Wnal volume was adjusted to 1 ml of 0.4 mg/ml collagen
type I with PBS and incubated at 30°C. Turbidity
change was measured by monitoring the change in
absorbance at 400 nm in a UV-160A Shimadzu spec-
trophotometer (Shimadzu Benelux, Den Bosch, NL) at
Wxed intervals. Data points represent the mean of trip-
licate measurements.
Binding assays
Ninety-six well microtiter plates (Greiner Bio-One
B.V., Alphen aan den Rijn, NL) were coated overnight
at 4°C with ECM components diluted in PBS. All fur-
ther incubation steps were performed at 37°C. After
each incubation step wells were washed with PBS con-
taining 0.05% Tween-20 (T-PBS). Wells were satu-
rated with 1% BSA in T-PBS for 2 h and then
incubated with recombinant TNX domains for 1 h.
This was followed by incubation with antibodies
against the recombinant TNX fragments for 1 h.
Thereafter, wells were incubated with biotinylated anti
guinea pig (Vector Laboratories Inc., Burlingame, CA,
USA), biotinylated anti rabbit (Vector Laboratories
Inc.) or anti mouse IgG (vectastain kit, Brunschwig
Chemie, Amsterdam, NL) for 1 h followed by a 45 min
incubation with an avidin–biotin–horse radish peroxi-
dase mixture (vectastain kit, Brunschwig Chemie).
Bound peroxidase was detected with o-phenylenedi-
amine dihydrochlorid (Perbio Science Nederland
B.V., Etten-Leur, NL) and the absorbance read at
490 nm. All antibodies and TNX proteins were
diluted in T-PBS containing 0.1% BSA. PBS was
substituted by tris buVered saline (TBS) + 5 mM
Ca2Cl2 in solid phase assays in which binding of TNX
to Wbrillin-1 domains was investigated for proper fold-
ing/stability of the Wbrillin-1 domains [7, 21]. Assays
were performed at least twice. BSA, MBP and pre
immunization guinea pig serum were used as negative
controls or baseline correction.
As an alternative to the binding assay in ELISA for-
mat we investigated binding of MBP–FNIII29 to colla-
gen Wbrils generated during the Wbrillogenesis assay.
BrieXy, various concentrations of MBP–FNIII29 were
incubated overnight at 30°C in the presence of 0.1%
BSA or collagen type I (0.4 mg/ml) + 0.1% BSA.
Thereafter, the insoluble collagen Wbrils were pelleted
by centrifugation. The concentration of MBP–FNIII29
in the supernatant was determined using an assay simi-
lar to a previous described one [22] in which, instead of
guinea pig anti TNX antiserum, fusion protein was
detected with monoclonal antibodies speciWc for MBP
(Westburg B.V.).
SDS-PAGE analysis
Proteins were loaded onto 12% Bis–Tris gels (Invitro-
gen) gel electrophoresis was carried out using the
NuPAGE system according to the manufacturer’s
instructions (Invitrogen). To analyze protein purity
gels were stained using coomassie brilliant blue R250
(Brunschwig).
Results
Binding of C-terminal 100 kDa TNX to extracellular 
matrix components
We postulated that TNX might interact with compo-
nents of elastic Wbers or collagens directly because of
the disturbed properties of collagens and elastic Wbers
in TNX deWcient patients. As a Wrst approach to iden-
tify extracellular ligands of TNX, we performed solid
phase assays to test binding of a recombinant C-termi-
nal 100 kDa TNX fragment [19, 23] (soluble phase) to
ECM molecules (immobilized substrates). Figure 1 a
shows that TNX binds dose dependently to human col-
lagens type I, III and V. Binding to BSA, which served
as a negative control, was absent. Figure 1b compares
the relative values of recombinant C-terminal 100 kDa
TNX binding to human Wbrillar collagens, at the high-
est concentration of fusion protein compared to the
control values of BSA. Figure 2 a shows the interaction
of TNX with bovine collagen type I, bovine tropoela-
stin and denatured collagen type I (gelatin). TNX did
not bind to denatured bovine collagen (gelatin).
Figure 2b compares the relative values of recombinant
C-terminal 100 kDa TNX binding to bovine tropoela-
stin, collagen type I and gelatin, at the highest concen-
tration of fusion protein compared to the control
values of BSA. Half maximal saturation, a measure for
the aYnity of the interaction, was reached at a concen-
tration of soluble 100 kDa TNX of 1.8 £ 10¡8 M for
human collagen type I and 4.0 £ 10¡8 M for bovine col-
lagen type I. Half maximal saturation was reached at
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1.1 £ 10¡8 M for human collagen type III, 0.8 £ 10¡8 M
for human collagen type V and 1.8 £ 10¡8 M for tropo-
elastin. We did not observe binding to several domains
of the elastic Wber protein Wbrillin-1 (data not shown).
Binding of speciWc C-terminal TNX fragments 
to extracellular matrix components
To identify the sequences in TNX responsible for bind-
ing to the ECM components we subcloned and
expressed a number of fragments from the C-terminal
100 kDa TNX protein. Figure 3 gives a schematic over-
view of these fragments, and shows the purity of the
fusion proteins used in this study. The domains studied
here were produced as MBP-fusion proteins and
included overlapping tandems of FNIII repeats and the
FbgX domain.
All recombinant proteins containing the FNIII29
repeat showed dose dependent binding to collagen
type I, III and V. As an example the binding curves for
collagen type V are shown in Fig. 4a. Only FNIII29,
FNIII28–29 and FNIII29–30 showed strong binding,
whereas no binding was observed for repeats FNIII27–
28, FNIII30–31 and the FbgX domain which yielded a
Xat line as for the MBP and BSA control. For reasons
of clarity the curves for FNIII27–28, FNIII30–31, FbgX
and BSA are not included in Fig. 4a because they coin-
cide with MBP. Figure 4b compares the relative values
of FNIII29 and FNIII27–28 binding to Wbrillar colla-
gens, at the highest concentration of fusion protein
compared to the control values of MBP.
Figure 5a depicts binding of TNX fragments to
recombinant bTE. All fusion proteins containing
FNIII29 were found to bind to TE, but in addition we
found interaction with the FbgX domain, which was
not the case for collagens. Recombinant MBP shows
some non-speciWc binding to bTE but this is clearly less
than FNIII29 and FbgX containing recombinant pro-
teins. This non-speciWc binding was also observed for
BSA, FNIII27–28 and FNIII30–31. The lines from
these proteins coincide with the line of the MBP con-
trol, therefore they were omitted from Fig. 5a for rea-
sons of clarity. Figure 5b compares the relative values
of FNIII29, FNIII27–28 and FbgX binding to recombi-
nant TE, at the highest concentration of fusion protein
compared to the control values of MBP.
We used TNX domains fused to MBP because this
allows simple high yield puriWcation and—impor-
tantly—it allows comparison and easy detection of
bound fusion proteins by a single anti-MBP antibody.
Fig. 1 Binding of recombinant C-terminal 100 kDa TNX to hu-
man collagen type I, III and V. a TNX binds dose dependently to
human collagens type I, III and V. Binding to BSA, which served
as a negative control, was absent. b Comparisons of binding of re-
combinant C-terminal 100 kDa TNX and BSA to collagens type
I, III, and V at the highest concentration used (10 M)
Fig. 2 Binding of recombinant C-terminal 100 kDa TNX to bo-
vine collagen type I and bTE. a TNX binds dose dependently to
bTE and bovine collagen type I. No binding to denatured bovine
collagen type I (gelatin) was observed (the gelatin signal coin-
cides with the BSA baseline signal). b Comparison of binding of
recombinant C-terminal 100 kDa TNX and BSA to collagens
type I, III and V at the highest concentration used (10 M)
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MBP alone was used as a control throughout the stud-
ies described above. In order to check if MBP fused to
TNX domains would cause artiWcial binding of fusion
proteins to ECM molecules we decided to test binding
of a recombinant TNX fragment without MBP. Unfor-
tunately, it was not possible to produce FNIII29 as a
single repeat protein without fusion protein tag in
either the pMal protein fusion or GST gene fusion sys-
tem. We therefore produced a recombinant FNIII29–
30 repeat devoid of fusion tag and raised an antibody
against FNIII29–30. Figure 6 shows that pure recombi-
nant FNIII29–30 essentially has the same binding prop-
erties towards Wbrillar collagens and TE as the MBP-
fusion protein, indicating that the interaction site
resides in the TNX moiety (FNIII29) of the fusion pro-
teins.
Stimulation of Wbrillogenesis by FNIII29
To extend the observed binding properties of TNX
FNIII repeats at the functional level, we investigated
whether the collagen binding FNIII29 repeat of human
TNX could modulate collagen Wbrillogenesis. Using a
turbidity assay (see Fig. 7a) we found an increase in the
rate of Wbril formation and a shortening of the lag
phase in the presence of the FNIII29 repeat of TNX
compared to the control proteins (BSA (not shown)
and MBP) The Wbrillogenesis rate in the lateral growth
phase, characterized by Wbril- and aggregate formation
[8, 26], was signiWcantly increased (P < 0.001) when
48 g/ml MBP–FNIII29 was added. At a concentration
of 24 g/ml, MBP–FNIII29 does not signiWcantly inXu-
ence the lateral growth phase, although it shortens the
lag phase, characterized by linear growth of microW-
brils and early Wbril formation [8, 26], compared to
controls. After 24 h all samples reached a similar maxi-
mal OD (data not shown). FNIII29–30 had only a min-
imal eVect on collagen Wbrillogenesis compared to
MBP–FNIII29 and C-terminal 100 kDa TNX showed
no signiWcant eVect on either the lag- or lateral growth
phase of collagen Wbrillogenesis (data not shown).
The Wbrillogenesis assay also provided us with an
alternative method to investigate binding of TNX frag-
ments to ECM molecules. To investigate the binding of
MBP–FNIII29 to the collagen Wbrils formed during the
assay, we measured the amount of MBP–FNIII29 that
Fig. 3 Recombinant TNX 
proteins used in this study. 
a Coomassie staining of
recombinant proteins, lanes 
1–5 MBP–FNIII repeats, lane 
6 MBP–FbgX domain, lane 7 
FNIII29–30 repeat without 
MBP fusion tag. b Schematic 
overview of recombinant pro-
teins
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remained in the supernatant after pelleting of the insol-
uble collagen Wbrils. As shown in Fig. 7b MBP–
FNIII29 was depleted from the soluble phase, indicat-
ing pull-down by the formation of collagen Wbrils.
Discussion
We established a number of novel in vitro binding
properties of human TNX that reside in the 100 kDa
C-terminal portion. The binding properties of this frag-
ment could be largely ascribed to the FbgX domain
(tropoelastin binding) and the FNIII29 repeat, which
was found to bind strongly to tropoelastin and collagen
types I, III and V. Previous studies by others, using
bovine and murine TNX have found binding to decorin
[4] and collagen type I [18]. In the latter study, deletion
of the EGF-like repeats or the FbgX domain did not
abolish collagen binding, suggesting that binding of
murine TNX resides somewhere in the FNIII repeats.
The binding to elastin was particularly interesting, as
abnormal elastic Wber morphology is a characteristic
feature of EDS patients with a complete TNX deW-
ciency. We found binding of tropoelastin both to
FNIII29 and FbgX. In contrast to FNIII29 the FbgX
domain only binds to TE and not to other tested ECM
proteins. The functional signiWcance of this Wnding
requires further investigation, but this interaction
could be involved both in maturation or stability of the
elastic Wber.
Dermal collagen deposition is reduced in TNX deW-
cient patients, and their skin and other connective tis-
sues is fragile as witnessed by easy bruising [22, 28].
The skin strength in TNX deWcient mice is markedly
reduced, although the signiWcance and magnitude of
the reduction of collagen deposition is debated [3, 15,
18]. In mice, the variation in collagen Wbril diameter
appears to be increased [15, 18]. Speculatively, the
assembly or stability of collagen Wbrils could be dis-
turbed in TNX deWcient patients. We found that the
FNIII29 domain of human TNX is able to accelerate
Fig. 4 Binding of TNX FNIII repeats to collagen type I, III an V.
a Binding curves of recombinant TNX proteins containing
FNIII29 show dose dependent binding to Wbrillar collagens as
shown here for human collagen type V. b Comparison of binding
of MBP–FNIII29, MBP-FNIII27–28 and MBP to collagens type I,
III and V at the highest concentration used (16 M)
Fig. 5 Binding of TNX FNIII repeats and FbgX domain to TE. a
Recombinant TNX fragments containing FNIII29 and the FbgX
domain bind dose dependently to recombinant TE. The other
investigated FNIII repeats of TNX do not show signiWcant bind-
ing to bTE (not shown here). MBP alone shows non-speciWc bind-
ing which is signiWcantly lower than the TNX containing fusion
proteins. b Comparison of binding of MBP-FNIII29, MBP–
FNIII27–28, MBP–FbgX and MBP to recombinant TE at the
highest concentration used (16 M)
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the collagen Wbril formation in vitro. In contrast, how-
ever, we failed to detect a signiWcant eVect of the
100 kDa TNX fragment on Wbrillogenesis. This might
possibly be due to conformational changes caused by
folding of the 100 kDa TNX in solution that precludes
an eVect on Wbrillogenesis, although the 100 kDa frag-
ment binds to collagen type I. Alternatively, the
observed eVect of the TNX FNIII29 repeat on Wbrillo-
genesis could be artiWcial, because it is not known
whether it is accessible to collagen in the native
450 kDa protein. Minamitani et al. found that a short
isoform of murine TNX could accelerate collagen
Wbrillogenesis in an assay similar to the one we used
[18]. Interestingly, they found that deletion of the EGF
repeats or Wbrinogen domain did not have an eVect on
binding of TNX to collagen although collagen Wbrillo-
genesis kinetics were aVected by deletion of these
domains. Possibly conformational changes could
account for this aVect. Furthermore, we observed bind-
ing of the TNX FNIII29 repeat to the insoluble colla-
gen Wbrils formed during in vitro Wbrillogenesis. This is
in agreement with the observed binding properties of
this domain in our solid phase assay in ELISA format.
For Wbrillar collagens type III and V we observed that
preincubation of TNX FNIII29 with these collagens
reduced the measured amount of TNX compared to
controls in a previously described TNX ELISA [22]
(data not shown). These Wndings are in accordance
with the results from our solid phase binding assays.
Clearly, the functional consequences of the interaction
of TNX domains require further investigation. Ideally,
the complete human 450 kDa [1] or adrenal speciWc
74 kDa [23] TNX form with correct glycosylation
should be produced or puriWed, to provide deWnitive
answers with respect to molecular interactions and
eVects on Wbrillogenesis. On the other hand, the molec-
ular diversity of TNX is far bigger than anticipated. We
have found that various fragments of TNX, ranging
from 70 to 450 kDa are present in human serum
(unpublished results). Whether these represent alter-
native splice forms or posttranslationally processed
fragments is unknown. All of these TNX forms contain
the FNIII29 repeat and it is possible that these shorter
forms adopt a conformation in which FNIII29 is
exposed to exert binding to ECM molecules and causes
functional eVects.
In conclusion, our study shows that domains of TNX
directly interact with a number of ECM molecules that
form a major part of the aVected structures in the der-
mis of TNX deWcient patients. Our data could serve as
a starting point to investigate the function of individ-
ual domains in the context of the physiological TNX
Fig. 6 Binding of FNIII29–30 to ECM proteins. Recombinant
FNIII29–30 (without fusion tag) binds to collagen types I, III and
V and to TE essentially in the same manner as the MBP fusion
proteins containing FNIII29. BSA is used as a control for back-
ground staining (7.5 g/ml)
Fig. 7 TNX FNIII29 aVects collagen Wbrillogenesis. a TNX
FNIII29 has a dose dependent eVect on the Wbrillogenesis rate of
bovine collagen type I in a turbidimetric assay. At a concentration
of 48 g/ml MBP–FNIII29 the Wbrillogenesis rate in the lateral
growth phase is signiWcantly increased. At a concentration of
24 g/ml MBP–FNIII29 does not signiWcantly inXuence the later-
al growth phase, although at both 24 and 48 g/ml the lag phase is
shortened. MBP and BSA served as a negative control. The
curves of BSA and 4.8 g/ml MBP–FNIII29 overlapped with the
MBP curve and have been omitted for reasons of clarity. b Com-
parison of TNX FNIII29 levels in the supernatant of pelleted
insoluble collagen Wbrils compared to controls. DiVerences of
TNX FNIII29 concentration in the supernatant reXect the
amount of TNX FNIII29 bound to the pelleted insoluble collagen
Wbrils
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molecules, like the 450 kDa tissue form or the various
serum forms. Further investigation of the role of TNX
in extracellular matrix assembly and stability will
increase our knowledge of connective tissue biology
and will oVer a molecular explanation for the pheno-
type of TNX deWcient patients.
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